SeaBird Exploration Plc
27.1.2021 14:48:59 CET | Globenewswire | Press release
27 January 2021, Limassol, Cyprus
SeaBird Exploration will present their financial results for the fourth quarter of 2020 on Friday 29 January at 08:00 CET. The presentation will be transmitted live and a recorded version will be available shortly thereafter. Please use the following link to join the webcast:
https://teams.microsoft.com/l/meetup-join/19%3ameeting_ZDlkZjhiODgtNTQwOS00Y2RmLTgwMjItZGIzMzhhMTEwMjYz%40thread.v2/0?context=%7b%22Tid%22%3a%22d7181576-1d07-4383-b8ac-6451ab33feae%22%2c%22Oid%22%3a%22ab38ca4b-0069-4d66-b5ab-30f40647842e%22%2c%22IsBroadcastMeeting%22%3atrue%7d
For further queries contact:
Erik von Krogh
CFO
Mob: +47 930 38 075
All statements in this press release other than statements of historical fact are forward-looking statements and are subject to a number of risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. These factors include SeaBird`s reliance on a cyclical industry and the utilization of the company's vessels. Actual results may differ substantially from those expected or projected in the forward-looking statements.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
UCB27.3.2026 07:00:00 CET | Press release
UCB - Convening Notice to the General Meeting of the Shareholders 2026
Arcadis N.V.27.3.2026 07:00:00 CET | Press release
Arcadis nominates Carl Trowell to its supervisory board
Novartis Pharma AG27.3.2026 07:00:00 CET | Press release
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
Novo Nordisk A/S27.3.2026 00:36:30 CET | Press release
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
DBV Technologies S.A.26.3.2026 22:19:05 CET | Press release
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
